In Reply We appreciate the comments of Hugon-Rodin et al and Ji and Chen and respond to the issues they raised. Hugon-Rodin et al raised the question of whether the relationship between β-blocker use and breast cancer risk varied when results were stratified according to type of β-blocker. As reported in our article,1 overall we found no relationship between current use or long-term current use (for ≥10 years) of β-blockers and risk of invasive ductal breast cancer (odds ratio [OR], 0.9 [95% CI, 0.7-1.2], and OR, 1.1 [95% CI, 0.7-1.8], respectively). No appreciable variations in risk were seen when we analyzed risks according to current use of β1-selective blockers vs nonselective β-blockers. Specifically, current users of β1-selective blockers of any duration and for 10 years or more had ORs of 0.9 (95% CI, 0.7-1.2) and 1.2 (95% CI, 0.7-1.9), respectively, and current users of nonselective β-blockers of any duration and for 10 years or more had ORs of 0.8 (95% CI, 0.4-1.6) and 0.8 (95% CI, 0.3-2.4), respectively. However, 90% of control women who were current β-blocker users were users of a β1-selective blocker (the other 10% were current users of nonselective β-blockers), limiting our power to detect differences in risk between β1-selective blockers vs nonselective β-blockers.
Li CI, Tang MC, Malone KE. Antihypertensive Medications and Breast Cancer Risk—Reply. JAMA Intern Med. 2014;174(4):641. doi:10.1001/jamainternmed.2013.13740